Abstract
Currently, most of the available chemotherapy has a narrow therapeutic window. This compromises the use of high-dose treatments in patients with advanced-stage cancers, who often need innovative strategies the most. Here, we present the conjugation of methotrexate with a novel cell-penetrating hexa-peptide (CPP6), a GFLG enzymatically cleavable spacer, and a short-length polyethylene glycol. The modifications added to methotrexate were rationalized to improve the drug bioavailability, specificity, and cell entry. Our final conjugate, CPGM, was successfully synthesized in solid phase and in vitro cell viability assays have shown that this conjugated form of methotrexate retains cytostatic effect towards MCF-7 breast cancer cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
